Compare Globus Medical Inc. Class A Common Stock (GMED) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Xylem, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Xylem, Inc. trades at $102.56 (market cap $23.94B). The key difference: Xylem, Inc. is far larger — about 2.3× Globus Medical Inc. Class A Common Stock's market cap, and Xylem, Inc. pays a 1.68% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| GMED | XYL | |
|---|---|---|
Market Cap | $10.25B | $23.94B |
Volume | 1,108,124 | 1,097,519 |
Sector | Health | Industrials |
52-Week High | $96.82 | $152.95 |
52-Week Low | $58.33 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $9.76B | $25.72B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Xylem (XYL) trades at $102.74, showing modest daily gains of 0.15%. The stock demonstrates strong fundamental performance with consistent earnings beats and revenue growth from $5.5B in 2022 to $9.0B in 2025. Technical indicators signal bearish momentum despite neutral oscillators, with key support at $101. Recent developments include strategic acquisitions of Cornell Pump and Roper Pump, strengthening the company's industrial water solutions portfolio.
Xylem presents a compelling investment case with solid profitability (11.15% net margin) and analyst consensus target of $146.63 offering 43% upside potential. However, technical weakness and China market challenges pose near-term risks. The company's focus on water infrastructure and digital solutions positions it well for long-term growth in essential water technology markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
